Specify a stock or a cryptocurrency in the search bar to get a summary
Aurinia Pharmaceuticals Inc
AUPHAurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada. Address: 118 Avenue , 14315, Edmonton, AB, Canada, T5L 4S6
Analytics
WallStreet Target Price
9.77 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures AUPH
Dividend Analytics AUPH
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History AUPH
Stock Valuation AUPH
Financials AUPH
Results | 2019 | Dynamics |